CIFoundry
Back to MammoScreen

Evaluation packet

MammoScreen

Therapixel · Oncology

Prepared November 22, 2026 from the public listing on CIFoundry. It shows what the public record says and what to ask the vendor. It is not a recommendation or an endorsement.

1. What the public record shows

Regulatory status
FDA ClearedFDA record
Published evidence
Not on record
Named health-system users
Integrations
Not on record
Data inputs
Not on record
HIPAA BAA
Not on record
SOC 2 / HITRUST
Not on record
Deployment model
Not on record

Integrations, data inputs, BAA, SOC 2, HITRUST and deployment model are reported by the vendor and not checked by us. Confirm them in writing.

2. Evaluation checklist for your role

Each question shows what the public record says: on record (with its source), reported by the maker, or not on record. It is a list of things to check, not a score.

For every reviewer

Physician

Your ticks and notes stay in this browser. Nothing is sent to us.

3. Gaps to raise with the vendor

Based on what is missing or worth confirming in this tool’s public record.

  1. Ask for the FDA decision summary. Check that your planned use matches the cleared intended use: patients, inputs (scanner, device, data type), users, and whether it assists a clinician or acts on its own.
  2. Ask whether the clearance includes a Predetermined Change Control Plan (PCCP), and how you will be told when the model changes.
  3. No published study is linked. Ask for peer-reviewed validation done outside the developer’s own sites, and for results on patients and equipment like yours.
  4. Will the vendor sign a HIPAA Business Associate Agreement?
  5. Does the vendor have a current SOC 2 Type II report or HITRUST certification you can review?
  6. Where is data stored and processed (cloud region, on-premises), and which subcontractors, including any large-language-model provider, touch patient data?
  7. How does it integrate with your EHR or imaging system, and where do results appear for the clinician?
  8. Is your data used to train the vendor’s models, and can it be deleted when the contract ends?

4. Questions for this kind of tool

From our Oncology AI guide.

Radiation contouring and planning

Use this section if the tool draws organs at risk or target volumes, or automates treatment planning.

Questions to ask

  • How much editing time does it save dosimetrists and physicians, and what share of contours are accepted with minor or no edits?
  • Which disease sites, scanners and planning systems was it validated on? Does it work with yours?
  • How are updates to the model handled, and are contours re-checked after an update?

Test it locally

  • Run it on 20 to 30 of your own cases per disease site and measure edit time and geometric agreement with your approved contours.

Red flags

  • Validated on only one planning system
  • No site-by-site results

Clinical-trial matching

Use this section if the tool screens patient records against trial eligibility criteria.

Questions to ask

  • Compared with coordinator review, how many suggested matches are truly eligible (precision), and how many eligible patients does it miss?
  • Does it read unstructured notes and pathology reports, or only structured data?
  • What is the effect on screen-to-enroll ratio and coordinator hours?

Measure

  • Screened, eligible and enrolled patients per trial, before and after go-live

Treatment decision support and outcome prediction

Use this section if the tool suggests treatment options or predicts survival, toxicity or response.

Questions to ask

  • Is there prospective evidence that it changes decisions or outcomes, not only retrospective accuracy?
  • How well do its recommendations agree with current guidelines (for example NCCN), and how quickly is it updated when guidelines change?
  • For predictions: is it calibrated in your population, and how was the outcome defined?

Red flags

  • Survival predictions without calibration data
  • No process for guideline updates

5. Questions for every tool

The 12 questions that apply to every tool

Fit and evidence

  • Intended use. Does the stated use match the patients, setting, user and decision you plan to use it for?
  • Evidence level. From weakest to strongest: vendor-internal test, retrospective external validation, prospective "silent" run, prospective live study, randomized trial, proven change in outcomes. Ask which level the claims rest on and look for peer-reviewed external validation.
  • Population and equipment. Ask for results by age, sex, race and ethnicity, language and payer, and, where relevant, skin type and body habitus. Ask for results on your scanner or device vendors, EHR and protocols.
  • Local validation. Before go-live, run the tool on your own recent cases and compare it to ground truth. Agree in the contract on what counts as passing.

Workflow and people

  • Workflow cost. Count clicks, alerts per clinician per shift, minutes added per case, and who acts on the output. A strong tool that nobody acts on has no value.
  • Integration. Native EHR or PACS integration or a separate window? Single sign-on? Where do results land?
  • Human oversight. Who has the final say, how are disagreements with the tool handled, and how do you guard against over-reliance? Train users on known failure modes, not just features. Explanations matter most for risk scores and decision support.

After go-live

  • Monitoring. Who checks for drift, how often, and what triggers a pause? Re-check after vendor updates, scanner or EHR changes, and shifts in your patient population. Agree in advance on the results that would retire the tool.
  • Model updates. Version control, advance notice of changes, and the right to stay on a version you validated.

Data, liability and money

  • Data rights and security. BAA, where data is stored and processed, encryption, retention, SOC 2 or HITRUST, whether your data trains the vendor's models, the list of subcontractors that touch patient data (including any large-language-model provider), and whether data can be deleted.
  • Liability and patient notice. Who is liable when AI-assisted care goes wrong is still unsettled, and responsibility currently stays with the clinicians and organizations using the tool. Ask your malpractice carrier, and cover indemnification, audit rights and incident reporting in the contract. Joint Commission and CHAI guidance says patients should be told when AI directly affects their care, with consent where relevant.
  • Money and exit. Pricing model, any real payment pathway, the return you will measure, termination for performance failure, data return, and no auto-renewal without a performance review.

6. Notes and decision

Problem we want to solve and how we will measure it

Vendor answers and follow-ups

Local test plan and what counts as passing

Decision, owner and next step

CIFoundry is an independent, vendor-neutral directory. Listing is free, and no one can pay to change a listing or this packet. Check every fact with the vendor and the primary source before relying on it.